<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Vasc Health Risk Manag</journal-id><journal-id journal-id-type="iso-abbrev">Vasc Health Risk Manag</journal-id><journal-id journal-id-type="publisher-id">Vascular Health and Risk
Management</journal-id><journal-title-group><journal-title>Vascular Health and Risk Management</journal-title></journal-title-group><issn pub-type="ppub">1176-6344</issn><issn pub-type="epub">1178-2048</issn><publisher><publisher-name>Dove Medical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23166441</article-id><article-id pub-id-type="pmc">3500143</article-id><article-id pub-id-type="doi">10.2147/VHRM.S37969</article-id><article-id pub-id-type="publisher-id">vhrm-8-621</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Treatment with exenatide once weekly or twice daily for 30 weeks is
associated with changes in several cardiovascular risk markers</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Chiquette</surname><given-names>Elaine</given-names></name><xref ref-type="aff" rid="af1-vhrm-8-621">1</xref><xref ref-type="corresp" rid="c1-vhrm-8-621"/></contrib><contrib contrib-type="author"><name><surname>Toth</surname><given-names>Peter P</given-names></name><xref ref-type="aff" rid="af2-vhrm-8-621">2</xref></contrib><contrib contrib-type="author"><name><surname>Ramirez</surname><given-names>Gilbert</given-names></name><xref ref-type="aff" rid="af3-vhrm-8-621">3</xref></contrib><contrib contrib-type="author"><name><surname>Cobble</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="af4-vhrm-8-621">4</xref></contrib><contrib contrib-type="author"><name><surname>Chilton</surname><given-names>Robert</given-names></name><xref ref-type="aff" rid="af5-vhrm-8-621">5</xref></contrib></contrib-group><aff id="af1-vhrm-8-621"><label>1</label>Amylin Pharmaceuticals, San Diego, CA</aff><aff id="af2-vhrm-8-621"><label>2</label>University of Illinois, Peoria, IL</aff><aff id="af3-vhrm-8-621"><label>3</label>Florida International University, Miami, FL</aff><aff id="af4-vhrm-8-621"><label>4</label>Atherotech, Birmingham, AL</aff><aff id="af5-vhrm-8-621"><label>5</label>University of Texas, San Antonio, TX, USA</aff><author-notes><corresp id="c1-vhrm-8-621">Correspondence: Elaine Chiquette, Amylin
Pharmaceuticals, 9360 Towne Centre Drive, San Diego, CA 92121, USA, Tel
+1 858 552 2200 ext 8093, Email
<email>elaine.chiquette@amylin.com</email></corresp></author-notes><pub-date pub-type="collection"><year>2012</year></pub-date><!--Dove Press titles changed from ppub to collections in 2009.
								Fake ppub written to satisfy Coll Date Type=ppub--><pub-date pub-type="ppub"><year>2012</year></pub-date><pub-date pub-type="epub"><day>12</day><month>11</month><year>2012</year></pub-date><volume>8</volume><fpage>621</fpage><lpage>629</lpage><permissions><copyright-statement>&#x000a9; 2012 Chiquette et al, publisher and licensee Dove Medical
Press Ltd.</copyright-statement><copyright-year>2012</copyright-year><license><license-p>This is an Open Access article which permits unrestricted noncommercial use,
provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Background</title><p>Dyslipidemia and type 2 diabetes are two of the most significant risk factors
for the development of cardiovascular disease. Measurement of lipoprotein
subclasses provides important information about derangements in lipid
metabolism and helps refine cardiovascular risk assessment. Exenatide, a
glucagon-like peptide 1 receptor agonist, improved glycemic control,
obesity, hypertension, and dyslipidemia in patients with type 2 diabetes in
clinical trials.</p></sec><sec><title>Methods</title><p>In the DURATION-1 trial, patients with type 2 diabetes were treated with
exenatide once weekly or twice daily for 30 weeks. This post hoc analysis
evaluated the impact of exenatide on lipoprotein subclasses in 211
DURATION-1 patients using vertical auto profile methodology and the
Statistical Package for the Social Sciences general linear model adjusted
for glycosylated hemoglobin (HbA<sub>1c</sub>) and weight.</p></sec><sec><title>Results</title><p>Baseline lipids and high sensitivity C-reactive protein were normal overall
based on the standard lipid panel. Once-weekly exenatide reduced
apolipoprotein B and the apolipoprotein B to apolipoprotein A1 ratio
(<italic>P</italic> &#x0003c; 0.05), independent of glycemic improvement and
weight loss. A significant shift in lipoprotein pattern away from small,
dense low-density lipoprotein-4 cholesterol was also observed
(<italic>P</italic> &#x0003c; 0.05). Exenatide once weekly increased
high-density lipoprotein-2 cholesterol, even after adjustment for changes in
HbA<sub>1c</sub> and weight (<italic>P</italic> &#x0003c; 0.05).
Triglycerides, very low-density lipoprotein cholesterol, and high
sensitivity C-reactive protein were reduced with both the once-weekly and
twice-daily exenatide regimens (<italic>P</italic> &#x0003c; 0.05).</p></sec><sec><title>Conclusion</title><p>In this post hoc analysis, exenatide significantly improved a number of
cardiovascular risk markers. Continuous exenatide exposure with exenatide
once weekly elicited a greater response than did immediate-release exenatide
twice daily, generally independent of glycemic improvement and weight loss.
Thus, in addition to improving glycemic control, exenatide induced favorable
changes in lipid and lipoprotein metabolism and decreased systemic
inflammation.</p></sec></abstract><kwd-group><kwd>glucagon-like protein-1 receptor agonist</kwd><kwd>incretin mimetic</kwd><kwd>dyslipidemia</kwd><kwd>type 2 diabetes mellitus</kwd></kwd-group></article-meta></front><body><sec><title>Introduction</title><p>Dyslipidemia in patients with type 2 diabetes increases the risk of cardiovascular
disease.<xref ref-type="bibr" rid="b1-vhrm-8-621">1</xref>&#x02013;<xref ref-type="bibr" rid="b3-vhrm-8-621">3</xref> In insulin-resistant states, such
as type 2 diabetes, there is greater constitutive mobilization of fatty acids from
triglyceride stores in visceral adipose tissue, increased hepatic secretion of very
low-density lipoprotein (VLDL) cholesterol, inhibition of lipoprotein lipase to some
degree, and activation of cholesteryl ester transfer protein. Given these metabolic
disturbances, the typical lipid profile in patients with type 2 diabetes includes
elevated triglycerides and VLDL cholesterol, increased numbers of small, dense
low-density lipoprotein (LDL) cholesterol and other atherogenic lipoproteins, and
reduced high-density lipoprotein (HDL) cholesterol.<xref ref-type="bibr" rid="b2-vhrm-8-621">2</xref></p><p>Reducing LDL cholesterol is the primary target of dyslipidemia therapy in both
primary and secondary prevention. However, LDL cholesterol incompletely assesses the
contribution of all atherogenic lipoproteins, such as VLDL or intermediate-density
lipoprotein (IDL), to cardiovascular disease risk. Direct measurement of circulating
apolipoprotein B concentrations has been proposed as a better method for assessing
this risk because it more accurately reflects the true burden of all atherogenic
lipoproteins.<xref ref-type="bibr" rid="b4-vhrm-8-621">4</xref></p><p>Restoration of glycemic control and relieving insulin resistance promotes reductions
in serum triglyceride levels, primarily by reducing free fatty acid and glucose
levels, both of which fuel hepatic triglyceride production. However, lowering of
glucose rarely results in pronounced improvements in LDL and HDL cholesterol or
their subclasses. Given the increased burden of cardiovascular risk factors in
patients with type 2 diabetes, it is critical to understand how current
antihyperglycemic agents impact these risk factors and the progression of
atherosclerosis, and to incorporate this knowledge into routine clinical practice.
For example, the InterHeart study reported that smoking, dyslipidemia, hypertension,
abdominal obesity, and diabetes account for 80% of the risk for an acute
myocardial infarction,<xref ref-type="bibr" rid="b5-vhrm-8-621">5</xref> and that
the strongest risk predictor is the ratio of apolipoprotein B to apolipoprotein A1.
Also, the Quebec Cardiovascular Study found that the combination of diabetes,
elevated small, dense LDL cholesterol, and elevated apolipoprotein B synergistically
confer a 20-fold increased risk for cardiovascular events.<xref ref-type="bibr" rid="b6-vhrm-8-621">6</xref> Other studies suggested that high sensitivity
C-reactive protein, a proinflammatory biomarker, helped to refine risk estimates
beyond the measurement of established Framingham risk factors.<xref ref-type="bibr" rid="b7-vhrm-8-621">7</xref> Nissen et al<xref ref-type="bibr" rid="b8-vhrm-8-621">8</xref> demonstrated that progression of atherosclerosis is
slower when atherogenic lipoprotein and high sensitivity C-reactive protein levels
are both reduced.</p><p>Exenatide is a glucagon-like protein-1 receptor agonist that has been demonstrated to
have multiple glucoregulatory effects in patients with type 2 diabetes, including
glucose-dependent enhancement of insulin secretion, suppression of inappropriately
high glucagon secretion, slowing of gastric emptying, and reduction of food intake,
usually accompanied by weight loss.<xref ref-type="bibr" rid="b9-vhrm-8-621">9</xref> Additional effects of exenatide are under investigation, including
improved endothelial function, reduced systolic blood pressure, decreased oxidative
stress and inflammation, and improved myocardial bioenergetics.<xref ref-type="bibr" rid="b10-vhrm-8-621">10</xref>&#x02013;<xref ref-type="bibr" rid="b13-vhrm-8-621">13</xref> Preliminary investigation with nuclear magnetic
resonance imaging demonstrated an exenatideinduced shift away from small LDL
lipoproteins towards larger, more buoyant LDL lipoproteins (small LDL cholesterol
change from baseline &#x02212;146 &#x000b1; 67 nmol/L, <italic>P</italic> =
0.037; large LDL cholesterol change from baseline 68 &#x000b1; 27 nmol/L,
<italic>P</italic> = 0.017) after 52 weeks of exenatide twice daily,
compared with biphasic insulin aspart, on a background of metformin and sulfonylurea
in patients with type 2 diabetes.<xref ref-type="bibr" rid="b14-vhrm-8-621">14</xref>,<xref ref-type="bibr" rid="b15-vhrm-8-621">15</xref></p><p>In this post hoc analysis of data from the 30-week DURATION- 1 (Diabetes Therapy
Utilization: Researching Changes in A<sub>1c</sub>, Weight and Other Factors Through
Intervention with Exenatide Once Weekly) clinical trial,<xref ref-type="bibr" rid="b16-vhrm-8-621">16</xref> the effects of two exenatide formulations
(immediate-release exenatide twice daily and extended-release exenatide once weekly)
on lipoproteins and high sensitivity C-reactive protein were explored using a
validated vertical auto profile ultracentrifuge methodology.<xref ref-type="bibr" rid="b17-vhrm-8-621">17</xref> This is the first comprehensive lipoprotein
subclass analysis performed for a glucagon-like protein-1 receptor agonist in human
patients with type 2 diabetes.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><p>Details on the DURATION-1 study (clinicaltrials.gov NCT00308139) have been reported
previously.<xref ref-type="bibr" rid="b16-vhrm-8-621">16</xref> In brief,
patients with type 2 diabetes were treated with exenatide 2 mg once weekly or
exenatide 10 &#x003bc;g twice daily for 30 weeks. Of the 295 intent-to-treat
patients in DURATION-1, 211 were assessed for lipid subclass concentrations at
baseline and week 30 using vertical auto profile technology,<xref ref-type="bibr" rid="b17-vhrm-8-621">17</xref> and constitute the analysis cohort. The vertical
auto profile method involves independent measurements of total cholesterol, HDL
cholesterol, and triglycerides.<xref ref-type="bibr" rid="b17-vhrm-8-621">17</xref>
The validated vertical auto profile technique is an inverted rate zonal, single
vertical spin, density gradient ultracentrifugation technique that simultaneously
and directly measures cholesterol concentrations of all five lipoprotein classes
(HDL cholesterol, LDL cholesterol-real [LDL cholesterol without
lipoprotein(a) and IDL cholesterol], VLDL cholesterol, IDL cholesterol,
lipoprotein(a)) and their subclasses.<xref ref-type="bibr" rid="b17-vhrm-8-621">17</xref>,<xref ref-type="bibr" rid="b18-vhrm-8-621">18</xref> The vertical
auto profile separates all lipoproteins in three steps: a two-layer density gradient
is prepared with the bottom layer containing a 1:40 serum dilution with KBr; the
gradient is centrifuged at 65,000 rpm for approximately 45&#x02013;60 minutes; and
the layers are analyzed using a continuous flow cholesterol analyzer. Output has
been validated against standardized reference tests from the Core Laboratory for
Clinical Studies at Washington University School of Medicine in St Louis, MO, using
beta quantification.<xref ref-type="bibr" rid="b19-vhrm-8-621">19</xref> High
sensitivity C-reactive protein was measured using the Multigent CRP Vario&#x02122;
assay (Ilex Medical Systems, Petach-Tikva, Israel) and the Architect
<italic>c</italic>8000<sup>&#x000ae;</sup> system for quantitative
immunoturbidometric determination (Abbott Diagnostics, Abbott Park, IL). Data were
analyzed using the Statistical Package for Social Sciences version 17.0 (IBM,
Armonk, NY) general linear model-univariate analysis. Outcome variables of interest
at study end were treated as dependent variables, adjusted for baseline and week 30
change in glycosylated hemoglobin (HbA<sub>1c</sub>) and weight. The statistical
significance level was set at <italic>P</italic> &#x0003c; 0.05.</p></sec><sec sec-type="results"><title>Results</title><p>General demographics and baseline values for the total analysis cohort are shown in
<xref ref-type="table" rid="t1-vhrm-8-621">Table 1</xref>. The patients were
generally middle-aged, obese Caucasians with a mean HbA<sub>1c</sub> of
8.2%. Approximately two thirds of the cohort were treated with metformin,
and more than half with a statin. In the total analysis cohort, mean baseline lipid
concentrations were generally within the normal range based on the standard lipid
panel.<xref ref-type="bibr" rid="b1-vhrm-8-621">1</xref>&#x02013;<xref ref-type="bibr" rid="b3-vhrm-8-621">3</xref> However, as shown below, there was
actually a preponderance of small, dense LDL cholesterol lipoproteins, and the LDL
cholesterol distribution in both treatment groups (exenatide once weekly or twice
daily) was skewed towards the smaller LDL3 cholesterol and LDL4 cholesterol. On
average, the more buoyant HDL2 cholesterol was below the recommended target
goal<xref ref-type="bibr" rid="b1-vhrm-8-621">1</xref>&#x02013;<xref ref-type="bibr" rid="b3-vhrm-8-621">3</xref> at baseline, with a resulting
apolipoprotein B to apolipoprotein A1 ratio above 0.6 (60%). Exenatide
treatment for 30 weeks significantly reduced mean HbA<sub>1c</sub> (exenatide once
weekly &#x02212;1.6%; exenatide twice daily &#x02212;1.2%) and body
weight from baseline (exenatide once weekly &#x02212;3.9 kg; exenatide twice daily
&#x02212;3.8 kg, <xref ref-type="fig" rid="f1-vhrm-8-621">Figure 1A and
B</xref>).</p><p>Lipoprotein and apoprotein measurements for the total cohort are shown in <xref ref-type="table" rid="t2-vhrm-8-621">Table 2</xref>, and week 30 changes after
adjustment for HbA<sub>1c</sub> and weight changes are shown in <xref ref-type="fig" rid="f1-vhrm-8-621">Figure 1C&#x02013;H</xref>. Exenatide once weekly
significantly reduced triglycerides, apolipoprotein B, the apolipoprotein B to
apolipoprotein A1 ratio, LDL4 cholesterol, and VLDL cholesterol (<italic>P</italic>
&#x0003c; 0.05). Exenatide twice daily reduced triglycerides and VLDL cholesterol
(<italic>P</italic> &#x0003c; 0.05). The changes in apolipoprotein A1, LDL
cholesterol, LDL1 cholesterol, LDL2 cholesterol, LDL3 cholesterol, IDL cholesterol,
VLDL3 cholesterol, VLDL1+2 cholesterol, non-HDL cholesterol, remnant
lipoproteins, and lipoprotein(a) cholesterol were not significant with either
treatment. Despite no statistically significant effect on total HDL cholesterol
after adjustment for changes in HbA<sub>1c</sub> and weight, exenatide once weekly
significantly increased HDL2 cholesterol (<italic>P</italic> &#x0003c; 0.05), but not
HDL3 cholesterol. In contrast, twice-daily treatment with exenatide resulted in no
change in HDL cholesterol subclasses.</p><p>Among patients with abnormal baseline lipid values,<xref ref-type="bibr" rid="b1-vhrm-8-621">1</xref>&#x02013;<xref ref-type="bibr" rid="b3-vhrm-8-621">3</xref> exenatide once weekly significantly improved apolipoprotein B, the
apolipoprotein B to apolipoprotein A1 ratio, LDL cholesterol, LDL3+4
cholesterol/LDL cholesterol, LDL1+2 cholesterol/ LDL cholesterol,
triglycerides, VLDL cholesterol, VLDL3 cholesterol, IDL cholesterol, non-HDL
cholesterol, and remnant lipoproteins (<italic>P</italic> &#x0003c; 0.05; <xref ref-type="fig" rid="f2-vhrm-8-621">Figure 2A&#x02013;E</xref>). Exenatide twice
daily improved apolipoprotein B, the apolipoprotein B to apolipoprotein A1 ratio,
LDL cholesterol, triglycerides, VLDL cholesterol, IDL cholesterol, non-HDL
cholesterol, and remnant lipoproteins (<italic>P</italic> &#x0003c; 0.05). Because
recommended HDL cholesterol concentrations differ by gender (&#x0003e;1.0 mmol/L in men
and &#x0003e;1.3 mmol/L in women),<xref ref-type="bibr" rid="b20-vhrm-8-621">20</xref>
these variables were evaluated separately for men and women. Results of these
analyses show that exenatide once weekly significantly improved HDL and HDL2
cholesterol in women, HDL and HDL3 cholesterol in men, and HDL2/HDL cholesterol in
both men and women (<italic>P</italic> &#x0003c; 0.05); exenatide twice daily
significantly improved HDL3 cholesterol in men and HDL cholesterol in both men and
women (<italic>P</italic> &#x0003c; 0.05). In the exenatide once-weekly treatment group,
the percentage of patients achieving lipoprotein normalization<xref ref-type="bibr" rid="b1-vhrm-8-621">1</xref>&#x02013;<xref ref-type="bibr" rid="b3-vhrm-8-621">3</xref> was 39% for LDL cholesterol, 36% for triglycerides,
50% for VLDL cholesterol, 42% for non-HDL cholesterol, and
20% for HDL cholesterol. In the exenatide twice-daily treatment group, the
percentage of patients achieving lipoprotein normalization<xref ref-type="bibr" rid="b1-vhrm-8-621">1</xref>&#x02013;<xref ref-type="bibr" rid="b3-vhrm-8-621">3</xref> was 39% for triglycerides, 55% for VLDL cholesterol,
18% for non-HDL cholesterol, and 15% for HDL cholesterol. During the
30-week assessment period, doses of lipid-lowering agents remained generally stable
in all patients in both treatment groups.</p><p>In the total cohort, both exenatide formulations reduced high sensitivity C-reactive
protein independent of glycemic control and weight loss (<italic>P</italic> &#x0003c;
0.05; <xref ref-type="fig" rid="f2-vhrm-8-621">Figure 2F</xref>). Among the patients
with abnormal high sensitivity C-reactive protein at baseline, high sensitivity
C-reactive protein was significantly reduced by 24% (<italic>P</italic>
= 0.018). The percentages achieving high sensitivity C-reactive protein
normalization (&#x0003c;3 mg/L) were 33% with exenatide once weekly and
38% with exenatide twice daily.</p></sec><sec sec-type="discussion"><title>Discussion</title><p>Evidence garnered over the past two decades has revealed the failure of standard
lipoprotein measurements (eg, triglycerides, total cholesterol, LDL cholesterol, and
HDL cholesterol) to identify many of the lipoprotein abnormalities contributing to
cardiovascular events.<xref ref-type="bibr" rid="b21-vhrm-8-621">21</xref> A recent
meta-analysis of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B as
markers of cardiovascular disease demonstrated that apolipoprotein B was the most
reliable predictor of fatal or nonfatal ischemic events.<xref ref-type="bibr" rid="b22-vhrm-8-621">22</xref> Across all studies analyzed, the mean
apolipoprotein B relative risk ratio was 12.0% greater than for LDL
cholesterol (<italic>P</italic> &#x0003c; 0.0001) and 5.7% higher than for
non-HDL cholesterol (<italic>P</italic> &#x0003c; 0.001). These head-to-head analyses
also rank-ordered the three markers as apolipoprotein B &#x0003e; non-HDL cholesterol
&#x0003e; LDL cholesterol. Over a 10-year period, an apolipoprotein B strategy would
prevent 500,000 more cardiovascular events than a non-HDL cholesterol strategy, and
a non-HDL cholesterol strategy would prevent 300,000 more cardiovascular events than
an LDL cholesterol strategy.<xref ref-type="bibr" rid="b22-vhrm-8-621">22</xref></p><p>Comprehensive lipoprotein testing, such as the vertical auto profile, can better
inform the clinician on the patient&#x02019;s underlying lipid disorders, above and
beyond the standard lipid panel, and can easily be incorporated into routine
clinical management. This potential benefit was demonstrated in a cohort of patients
with type 2 diabetes from the DURATION-1 exenatide clinical trial,<xref ref-type="bibr" rid="b16-vhrm-8-621">16</xref> in which there was a
preponderance of small, dense LDL cholesterol lipoproteins (see <xref ref-type="table" rid="t1-vhrm-8-621">Table 1</xref>) not apparent from the
standard lipid panel.<xref ref-type="bibr" rid="b1-vhrm-8-621">1</xref>&#x02013;<xref ref-type="bibr" rid="b3-vhrm-8-621">3</xref> In fact,
the LDL cholesterol distribution in both treatment groups (exenatide once weekly,
exenatide twice daily) was skewed towards the smaller LDL3 cholesterol and LDL4
cholesterol. On average, the more buoyant HDL2 cholesterol was below the recommended
target goal<xref ref-type="bibr" rid="b1-vhrm-8-621">1</xref>&#x02013;<xref ref-type="bibr" rid="b3-vhrm-8-621">3</xref> at baseline, with a resulting
apolipoprotein B to apolipoprotein A1 ratio above 0.6 (60%). Clearly, the
most widely used clinical test failed to capture the level of cardiovascular risk
accurately in these patients.</p><p>Despite the appearance of a benign lipid profile at baseline based on the standard
lipid panel,<xref ref-type="bibr" rid="b1-vhrm-8-621">1</xref>&#x02013;<xref ref-type="bibr" rid="b3-vhrm-8-621">3</xref> a clinically important shift in
lipoprotein pattern away from small, dense LDL4 cholesterol particles was observed
with once-weekly exenatide treatment. This is consistent with the reduction in serum
triglycerides that was also observed in patients treated with exenatide once weekly.
As triglyceride availability in serum decreases, there is less cholesteryl ester
transfer protein-dependent loading of LDL cholesterol particles with triglyceride.
This, is turn, results in less hepatic lipase-dependent lipolysis of LDL cholesterol
particles, allowing for them to remain larger, more buoyant, and possibly less
atherogenic. Exenatide once weekly also significantly increased the levels of more
buoyant HDL2 cholesterol particles, even after adjustment for treatment effects on
HbA<sub>1c</sub> and body weight. This shift suggests that HDL cholesterol
particles in exenatide-treated patients are maturing, and may not be as vulnerable
to lipolysis and catabolism by hepatic lipase. Although the subject of debate,
investigations have suggested that the HDL2 cholesterol subtype may have a greater
cardioprotective effect in type 2 diabetes.<xref ref-type="bibr" rid="b23-vhrm-8-621">23</xref> Given that the pathogenic potential of small
dense LDL cholesterol and apolipoprotein B may be further amplified by insulin
resistance and the hyperglycemia of type 2 diabetes, the additional 4%
reduction in apolipoprotein B, 1.6% reduction in HbA<sub>1c</sub>, and 4 kg
weight loss observed with exenatide therapy in this study would be expected to
contribute to overall risk reduction. Considering the changes in serum levels of
apolipoproteins, lipids, and lipoproteins observed in this cohort, at a minimum,
exenatide therapy was associated with improvements in lipoprotein metabolism.</p><p>Hypertriglyceridemia is a marker of metabolic disease, and is assuming an
increasingly important role in the assessment and management of cardiovascular
disease risk.<xref ref-type="bibr" rid="b24-vhrm-8-621">24</xref> Prospective
studies support a strong link between triglyceride concentrations and cardiovascular
risk in patients with type 2 diabetes, and in individuals with lower levels of HDL
and LDL cholesterol. The incomplete hydrolysis of triglyceride-rich chylomicrons and
VLDL particles results in atherogenic cholesterol-enriched remnant lipoproteins and
elevated nonfasting triglycerides that have been strongly correlated with high
levels of remnant lipoproteins. In our post hoc analysis, both exenatide
formulations significantly reduced circulating concentrations of triglycerides and
VLDL cholesterol. The beneficial effects of exenatide on the entire spectrum of
apolipoproteins, lipoproteins, and lipoprotein subclasses were especially apparent
in patients with abnormal baseline values. Exenatide treatment improved
apolipoprotein B, LDL cholesterol, and several subclass risk indicators, including a
number of other atherogenic cholesterol-rich lipoproteins, triglycerides, and
antiatherogenic HDL cholesterol, HDL2 cholesterol, and HDL3 cholesterol.</p><p>Several previous studies offer additional insights into the effects of exenatide on
circulating lipids and lipoproteins.<xref ref-type="bibr" rid="b10-vhrm-8-621">10</xref>&#x02013;<xref ref-type="bibr" rid="b12-vhrm-8-621">12</xref>,<xref ref-type="bibr" rid="b25-vhrm-8-621">25</xref>&#x02013;<xref ref-type="bibr" rid="b29-vhrm-8-621">29</xref> In an open-label extension of the first three
Phase III exenatide twice daily clinical trials, 314 patients with type 2 diabetes
treated with metformin and/or sulfonylurea plus exenatide twice daily for 82 weeks
had significantly reduced triglycerides (&#x02212;0.43 mmol/L) and elevated HDL
cholesterol (+0.12 mmol/L).<xref ref-type="bibr" rid="b25-vhrm-8-621">25</xref> There were trends for reductions in total cholesterol, apolipoprotein
B, and LDL cholesterol. By 3.5 years of twice-daily exenatide treatment, the 151
evaluable patients had significant reductions from baseline in triglycerides
(&#x02212;12%), total cholesterol (&#x02212;5%), and LDL cholesterol
(&#x02212;6%).<xref ref-type="bibr" rid="b26-vhrm-8-621">26</xref> In
addition, HDL cholesterol was significantly increased by 24%. Although the
25% of patients who lost the most weight had the greatest improvements in
triglycerides and HDL cholesterol, there was minimal correlation between weight
change and lipid improvements for the total cohort. Correlations between
HbA<sub>1c</sub> or fasting plasma glucose and serum lipid concentrations were
similarly low. In a clinical practice setting, Bhushan et al<xref ref-type="bibr" rid="b10-vhrm-8-621">10</xref> reported a retrospective analysis of the
laboratory and medical records of 176 adults with both type 2 diabetes and metabolic
syndrome treated with exenatide twice daily for 16 weeks. Exenatide significantly
reduced total cholesterol and LDL cholesterol, but not triglycerides. Of interest,
these results were not attributable to changes in concomitant dyslipidemia
medications. In a later clinical trial, Bunck et al<xref ref-type="bibr" rid="b11-vhrm-8-621">11</xref> evaluated 69 patients with type 2 diabetes
treated chronically with metformin and exenatide twice daily or insulin glargine for
a year. Compared with insulin, exenatide twice daily significantly reduced post-meal
excursions in triglycerides, apolipoprotein B48, VLDL cholesterol, and free fatty
acids, and increased HDL cholesterol. Finally, acute exenatide administration
suppressed postprandial excursions of proatherogenic lipoproteins in overweight/
obese adults with impaired glucose tolerance or recent onset type 2 diabetes
(57% treated with statins).<xref ref-type="bibr" rid="b12-vhrm-8-621">12</xref>,<xref ref-type="bibr" rid="b27-vhrm-8-621">27</xref> One injection of
exenatide markedly reduced postprandial elevation of triglycerides, apolipoprotein
B-48, apolipoprotein CIII, remnant lipoprotein cholesterol, and remnant lipoprotein
triglyceride (each <italic>P</italic> &#x0003c; 0.05 versus placebo). A subgroup analysis
found that postprandial endothelial function was higher after exenatide than after
placebo (<italic>P</italic> = 0.0002) and that exenatide-induced changes in
postprandial triglyceride concentrations explained 64% of this effect.
Further, the effects of exenatide on postprandial lipoproteins were not affected by
the degree of loss of glucose control nor by dyslipidemia treatment with statins. In
the DURATION-2 study, patients with type 2 diabetes suboptimally controlled with
metformin and treated with exenatide once weekly for 26 weeks had significantly
increased HDL cholesterol compared with baseline (<italic>P</italic> &#x0003c;
0.05),<xref ref-type="bibr" rid="b28-vhrm-8-621">28</xref> and this improvement
was maintained out to 52 weeks.<xref ref-type="bibr" rid="b29-vhrm-8-621">29</xref>
Taken together, these data lend further support to a role for exenatide in improving
the typical diabetic proatherogenic profile that is at least partially independent
of the effects of exenatide on glycemic control and weight loss. Although little is
known concerning potential mechanisms to explain the effects of exenatide on
lipoproteins, in a recent study, exenatide acutely suppressed intestinal lipoprotein
production, possibly through a direct effect on intestinal lipoprotein production,
but independent of changes in body weight, satiety, gastric emptying, glucagon, and
circulating free fatty acid concentrations.<xref ref-type="bibr" rid="b30-vhrm-8-621">30</xref></p><p>The interplay between proinflammatory cytokines and lipid homeostasis has been well
described.<xref ref-type="bibr" rid="b31-vhrm-8-621">31</xref> Type 2 diabetes
is associated with a chronically heightened level of systemic inflammation
characterized by increased plasma levels of numerous inflammatory biomarkers,
including high sensitivity C-reactive protein. In a large, representative study, the
relationship between circulating levels of high sensitivity C-reactive protein and
cardiovascular disease mortality was tracked over 7 years.<xref ref-type="bibr" rid="b32-vhrm-8-621">32</xref> In these patients, individuals with a baseline
high sensitivity C-reactive protein &#x0003e; 3 mg/L were significantly more likely to
die from cardiovascular disease (about 1.5- fold) than were individuals with high
sensitivity C-reactive protein &#x02264; 3 mg/L (<italic>P</italic> &#x0003c; 0.004).
Furthermore, this association remained even after adjustment for age, gender, total
cholesterol, HDL cholesterol, triglycerides, diabetes duration, HbA<sub>1c</sub>,
hypertension, smoking, residence area, and body mass index, and was independent of
pre-existing myocardial infarction events.</p><p>Exenatide treatment was observed to reduce high sensitivity C-reactive protein
significantly, independent of glycemic control and weight loss in the total
lipid-analysis cohort. When patients with type 2 diabetes suboptimally controlled
with metformin and/or sulfonylurea were treated with exenatide twice daily for 16
weeks, high sensitivity C-reactive protein was significantly reduced (from 0.4
&#x000b1; 0.5 to 0.2 &#x000b1; 0.3 mg/L) compared with placebo (increased from 0.6
&#x000b1; 0.4 to 1.4 &#x000b1; 1.6 mg/L; <italic>P</italic> &#x0003c; 0.05).<xref ref-type="bibr" rid="b33-vhrm-8-621">33</xref> In the DURATION- 2 study,
patients whose type 2 diabetes was suboptimally controlled with metformin and who
were treated with exenatide once weekly for 26 weeks had significantly reduced high
sensitivity C-reactive protein (<italic>P</italic> &#x0003c; 0.05),<xref ref-type="bibr" rid="b28-vhrm-8-621">28</xref> and this improvement reached &#x02212;25%
by week 52.<xref ref-type="bibr" rid="b29-vhrm-8-621">29</xref></p><p>The limitations of this study include the post hoc nature of the analysis, the small
number of patients, especially those with abnormal baseline values, and the
open-label treatment design. Furthermore, these analyses were exploratory in nature,
and the results should be considered primarily as hypothesis generating.</p></sec><sec><title>Conclusion</title><p>This post hoc analysis demonstrated that exenatide therapy may improve a wide
spectrum of cardiovascular disease risk markers. Continuous exenatide exposure with
once-weekly administration elicited a greater response than exenatide twice daily.
Importantly, these improvements were at least partially mediated through mechanisms
distinct from the effects of exenatide on hyperglycemia and obesity. Thus,
administration of once-weekly exenatide has the potential to modify cardiovascular
disease risk factors beneficially in patients with type 2 diabetes and, thus,
warrants further clinical investigation in prospective studies. An ongoing,
prospective morbidity and mortality outcomes study (EXSCEL, clinicaltrials.gov
NCT01144338) is expected to elucidate further the potential cardiovascular benefits
stemming from the effect of exenatide once weekly on dyslipidemia.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors thank and acknowledge medical writing and data analyses by Loretta L
Nielsen, LLNielsen Medical Writing, and data compilation by Carl LaCerte, Amylin
Pharmaceuticals Inc.</p></ack><fn-group><fn id="fn1-vhrm-8-621"><p><bold>Disclosure</bold></p><p>EC is an employee and stockholder of Amylin Pharmaceuticals Inc. PT is a
consultant for AstraZeneca, Abbott Laboratories, Genzyme, Genentech, Kowa, and
Merck, and a member of the speakers&#x02019; bureau for AstraZeneca, Abbott
Laboratories, Boehringer-Ingelheim, GSK, Kowa, Merck, and Takeda. GR is an
employee of Florida International University and has no other financial
conflicts of interest to disclose. MC is a member of the speakers&#x02019;
bureau or advisory boards for Abbott Laboratories, AstraZeneca,
Boehringer-Ingelheim, Bristol- Meyers-Squib, Eli Lilly and Company, Forest
Pharmaceuticals, Genetech/Roche, and Kowa. He has served as a continuing medical
education speaker for PriMed, and is a board member for the not-for-profit Utah
Healthy Living Foundation. MC is also the chief medical officer for Atherotech
Cardiometabolic Diagnostic Laboratory and has received research funding from the
Johnson and Johnson Research Institute. RC is associated with the following
companies as a consultant: Amylin Pharmaceuticals Inc, Eli Lilly and Company,
Hoffman- La-Roche, Pfizer, AstraZeneca, Boehringer- Ingelheim, Boston
Scientific, Endosonics, Medicines Company, Forest Pharmaceuticals, Medtronics,
and Novo Nordisk. Parts of this study were presented in abstract form at the
47th Annual Meeting of the European Association for the Study of Diabetes,
Lisbon, Portugal, September 12&#x02013;16, 2011.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-vhrm-8-621"><label>1</label><element-citation publication-type="journal"><collab>NCEP Expert
Panel</collab><article-title>Third Report of the National Cholesterol
Education Program (NCEP) Expert Panel on Detection, Evaluation, and
Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
final
report</article-title><source>Circulation</source><year>2002</year><volume>106</volume><issue>25</issue><fpage>3143</fpage><lpage>3421</lpage><pub-id pub-id-type="pmid">12485966</pub-id></element-citation></ref><ref id="b2-vhrm-8-621"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brunzell</surname><given-names>JD</given-names></name><name><surname>Davidson</surname><given-names>M</given-names></name><name><surname>Furberg</surname><given-names>CD</given-names></name><etal/></person-group><article-title>Lipoprotein management in patients with
cardiometabolic risk: consensus statement from the American Diabetes
Association and the American College of Cardiology
Foundation</article-title><source>Diabetes
Care</source><year>2008</year><volume>31</volume><issue>4</issue><fpage>811</fpage><lpage>822</lpage><pub-id pub-id-type="pmid">18375431</pub-id></element-citation></ref><ref id="b3-vhrm-8-621"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Catapano</surname><given-names>AL</given-names></name><name><surname>Reiner</surname><given-names>Z</given-names></name><name><surname>De Backer</surname><given-names>G</given-names></name><etal/></person-group><article-title>ESC/EAS guidelines for the management of
dyslipidaemias. The Task Force for the management of dyslipidaemias of the
European Society of Cardiology (ESC) and the European Atherosclerosis
Society
(EAS)</article-title><source>Atherosclerosis</source><year>2011</year><volume>217S</volume><fpage>S1</fpage><lpage>S44</lpage><pub-id pub-id-type="pmid">21723445</pub-id></element-citation></ref><ref id="b4-vhrm-8-621"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Contois</surname><given-names>JH</given-names></name><name><surname>McConnell</surname><given-names>JP</given-names></name><name><surname>Sethi</surname><given-names>AA</given-names></name><etal/></person-group><article-title>Apolipoprotein B and cardiovascular disease risk:
position statement from the AACC Lipoproteins and Vascular Diseases Division
Working Group on Best Practices</article-title><source>Clin
Chem</source><year>2009</year><volume>55</volume><issue>3</issue><fpage>407</fpage><lpage>419</lpage><pub-id pub-id-type="pmid">19168552</pub-id></element-citation></ref><ref id="b5-vhrm-8-621"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yusuf</surname><given-names>S</given-names></name><name><surname>Hawken</surname><given-names>S</given-names></name><name><surname>Ounpuu</surname><given-names>S</given-names></name><etal/></person-group><article-title>Effect of potentially modifiable risk factors
associated with myocardial infarction in 52 countries (the INTERHEART
study): case-control
study</article-title><source>Lancet</source><year>2004</year><volume>364</volume><issue>9438</issue><fpage>937</fpage><lpage>952</lpage><pub-id pub-id-type="pmid">15364185</pub-id></element-citation></ref><ref id="b6-vhrm-8-621"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>St-Pierre</surname><given-names>AC</given-names></name><name><surname>Cantin</surname><given-names>B</given-names></name><name><surname>Dagenais</surname><given-names>GR</given-names></name><etal/></person-group><article-title>Low-density lipoprotein subfractions and the
long-term risk of ischemic heart disease in men: 13-year follow-up data from
the Quebec Cardiovascular Study</article-title><source>Arterioscler Thromb
Vasc
Biol</source><year>2005</year><volume>25</volume><issue>3</issue><fpage>553</fpage><lpage>559</lpage><pub-id pub-id-type="pmid">15618542</pub-id></element-citation></ref><ref id="b7-vhrm-8-621"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holme</surname><given-names>I</given-names></name><name><surname>Aastveit</surname><given-names>AH</given-names></name><name><surname>Hammar</surname><given-names>N</given-names></name><name><surname>Jungner</surname><given-names>I</given-names></name><name><surname>Walldius</surname><given-names>G</given-names></name></person-group><article-title>Inflammatory markers, lipoprotein components and
risk of major cardiovascular events in 65,005 men and women in the
Apolipoprotein MOrtality RISk study
(AMORIS)</article-title><source>Atherosclerosis</source><year>2010</year><volume>213</volume><issue>1</issue><fpage>299</fpage><lpage>305</lpage><pub-id pub-id-type="pmid">20843515</pub-id></element-citation></ref><ref id="b8-vhrm-8-621"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nissen</surname><given-names>SE</given-names></name><name><surname>Tuzcu</surname><given-names>EM</given-names></name><name><surname>Schoenhagen</surname><given-names>P</given-names></name><etal/></person-group><article-title>Statin therapy, LDL cholesterol, C-reactive
protein, and coronary artery disease</article-title><source>N Engl J
Med</source><year>2005</year><volume>352</volume><issue>1</issue><fpage>29</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">15635110</pub-id></element-citation></ref><ref id="b9-vhrm-8-621"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drucker</surname><given-names>DJ</given-names></name><name><surname>Sherman</surname><given-names>SI</given-names></name><name><surname>Gorelick</surname><given-names>FS</given-names></name><name><surname>Bergenstal</surname><given-names>RM</given-names></name><name><surname>Sherwin</surname><given-names>RS</given-names></name><name><surname>Buse</surname><given-names>JB</given-names></name></person-group><article-title>Incretin-based therapies for the treatment of type
2 diabetes: evaluation of the risks and
benefits</article-title><source>Diabetes
Care</source><year>2010</year><volume>33</volume><issue>2</issue><fpage>428</fpage><lpage>433</lpage><pub-id pub-id-type="pmid">20103558</pub-id></element-citation></ref><ref id="b10-vhrm-8-621"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhushan</surname><given-names>R</given-names></name><name><surname>Elkind-Hirsch</surname><given-names>KE</given-names></name><name><surname>Bhushan</surname><given-names>M</given-names></name><name><surname>Butler</surname><given-names>WJ</given-names></name><name><surname>Duncan</surname><given-names>K</given-names></name><name><surname>Marrioneaux</surname><given-names>O</given-names></name></person-group><article-title>Improved glycemic control and reduction of
cardiometabolic risk factors in subjects with type 2 diabetes and metabolic
syndrome treated with exenatide in a clinical practice
setting</article-title><source>Diabetes Technol
Ther</source><year>2009</year><volume>11</volume><issue>6</issue><fpage>353</fpage><lpage>359</lpage><pub-id pub-id-type="pmid">19459763</pub-id></element-citation></ref><ref id="b11-vhrm-8-621"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bunck</surname><given-names>MC</given-names></name><name><surname>Corn&#x000e9;r</surname><given-names>A</given-names></name><name><surname>Eliasson</surname><given-names>B</given-names></name><etal/></person-group><article-title>One-year treatment with exenatide vs insulin
glargine: effects on postprandial glycemia, lipid profiles, and oxidative
stress</article-title><source>Atherosclerosis</source><year>2010</year><volume>212</volume><issue>1</issue><fpage>223</fpage><lpage>229</lpage><pub-id pub-id-type="pmid">20494360</pub-id></element-citation></ref><ref id="b12-vhrm-8-621"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koska</surname><given-names>J</given-names></name><name><surname>Schwartz</surname><given-names>EA</given-names></name><name><surname>Mullin</surname><given-names>MP</given-names></name><name><surname>Schwenke</surname><given-names>DC</given-names></name><name><surname>Reaven</surname><given-names>PD</given-names></name></person-group><article-title>Improvement of postprandial endothelial function
after a single dose of exenatide in individuals with impaired glucose
tolerance and recent-onset type 2 diabetes</article-title><source>Diabetes
Care</source><year>2010</year><volume>33</volume><issue>5</issue><fpage>1028</fpage><lpage>1030</lpage><pub-id pub-id-type="pmid">20200309</pub-id></element-citation></ref><ref id="b13-vhrm-8-621"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okerson</surname><given-names>T</given-names></name><name><surname>Yan</surname><given-names>P</given-names></name><name><surname>Stonehouse</surname><given-names>A</given-names></name><name><surname>Brodows</surname><given-names>R</given-names></name></person-group><article-title>Effects of exenatide on systolic blood pressure in
subjects with type 2 diabetes</article-title><source>Am J
Hypertens</source><year>2010</year><volume>23</volume><issue>3</issue><fpage>334</fpage><lpage>339</lpage><pub-id pub-id-type="pmid">20019672</pub-id></element-citation></ref><ref id="b14-vhrm-8-621"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nauck</surname><given-names>MA</given-names></name><name><surname>Duran</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>D</given-names></name><etal/></person-group><article-title>A comparison of twice-daily exenatide and biphasic
insulin aspart in patients with type 2 diabetes who were suboptimally
controlled with sulfonylurea and metformin: a non-inferiority
study</article-title><source>Diabetologia</source><year>2007</year><volume>50</volume><issue>2</issue><fpage>259</fpage><lpage>267</lpage><pub-id pub-id-type="pmid">17160407</pub-id></element-citation></ref><ref id="b15-vhrm-8-621"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kapitza</surname><given-names>C</given-names></name><name><surname>Nauck</surname><given-names>M</given-names></name><name><surname>Trautmann</surname><given-names>M</given-names></name><etal/></person-group><article-title>Long-term treatment with exenatide was associated
with improved post-prandial glycaemic control and a shift from small to
large HDL and LDL particles</article-title><source>Diabet
Med</source><year>2006</year><volume>23</volume><issue>Suppl
4</issue><fpage>S4</fpage></element-citation></ref><ref id="b16-vhrm-8-621"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drucker</surname><given-names>DJ</given-names></name><name><surname>Buse</surname><given-names>JB</given-names></name><name><surname>Taylor</surname><given-names>K</given-names></name><etal/></person-group><article-title>Exenatide once weekly versus twice daily for the
treatment of type 2 diabetes: a randomised, open-label, non-inferiority
study</article-title><source>Lancet</source><year>2008</year><volume>372</volume><issue>9645</issue><fpage>1240</fpage><lpage>1250</lpage><pub-id pub-id-type="pmid">18782641</pub-id></element-citation></ref><ref id="b17-vhrm-8-621"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kulkarni</surname><given-names>KR</given-names></name></person-group><article-title>Cholesterol profile measurement by vertical auto
profile method</article-title><source>Clin Lab
Med</source><year>2006</year><volume>2694</volume><fpage>787</fpage><lpage>802</lpage><pub-id pub-id-type="pmid">17110240</pub-id></element-citation></ref><ref id="b18-vhrm-8-621"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kulkarni</surname><given-names>KR</given-names></name><name><surname>Garber</surname><given-names>DW</given-names></name><name><surname>Marcovina</surname><given-names>SM</given-names></name><name><surname>Segrest</surname><given-names>JP</given-names></name></person-group><article-title>Quantification of cholesterol in all lipoprotein
classes by the VAP-II method</article-title><source>J Lipid
Res</source><year>1994</year><volume>35</volume><issue>1</issue><fpage>159</fpage><lpage>168</lpage><pub-id pub-id-type="pmid">8138718</pub-id></element-citation></ref><ref id="b19-vhrm-8-621"><label>19</label><element-citation publication-type="webpage"><collab>Atherotech Diagnostics Lab</collab><source>The
VAP cholesterol test</source><year>2012</year><comment>Available from:
<ext-link ext-link-type="uri" xlink:href="http://www.atherotech.com">http://www.atherotech.com</ext-link></comment><date-in-citation>Accessed
October 14, 2011</date-in-citation></element-citation></ref><ref id="b20-vhrm-8-621"><label>20</label><element-citation publication-type="journal"><comment>[No authors
listed]</comment><article-title>Standards of medical care in
diabetes &#x02013; 2012</article-title><source>Diabetes
Care</source><year>2012</year><volume>35</volume><issue>Suppl
1</issue><fpage>S11</fpage><lpage>S63</lpage><pub-id pub-id-type="pmid">22187469</pub-id></element-citation></ref><ref id="b21-vhrm-8-621"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Superko</surname><given-names>HR</given-names></name></person-group><article-title>Advanced lipoprotein testing and subfractionation
are clinically
useful</article-title><source>Circulation</source><year>2009</year><volume>119</volume><issue>17</issue><fpage>2383</fpage><lpage>2395</lpage><pub-id pub-id-type="pmid">19414656</pub-id></element-citation></ref><ref id="b22-vhrm-8-621"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sniderman</surname><given-names>AD</given-names></name><name><surname>Williams</surname><given-names>K</given-names></name><name><surname>Contois</surname><given-names>JH</given-names></name><etal/></person-group><article-title>A meta-analysis of low-density lipoprotein
cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B
as markers of cardiovascular risk</article-title><source>Circ Cardiovasc
Qual
Outcomes</source><year>2011</year><volume>4</volume><issue>3</issue><fpage>337</fpage><lpage>345</lpage><pub-id pub-id-type="pmid">21487090</pub-id></element-citation></ref><ref id="b23-vhrm-8-621"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franceschini</surname><given-names>G</given-names></name><name><surname>Bondioli</surname><given-names>A</given-names></name><name><surname>Granata</surname><given-names>D</given-names></name><etal/></person-group><article-title>Reduced HDL2 levels in myocardial infarction
patients without risk factors for
atherosclerosis</article-title><source>Atherosclerosis</source><year>1987</year><volume>68</volume><issue>3</issue><fpage>213</fpage><lpage>219</lpage><pub-id pub-id-type="pmid">3426654</pub-id></element-citation></ref><ref id="b24-vhrm-8-621"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>M</given-names></name><name><surname>Stone</surname><given-names>NJ</given-names></name><name><surname>Ballantyne</surname><given-names>C</given-names></name><etal/></person-group><article-title>Triglycerides and cardiovascular disease: a
scientific statement from the American Heart
Association</article-title><source>Circulation</source><year>2011</year><volume>123</volume><issue>20</issue><fpage>2292</fpage><lpage>2333</lpage><pub-id pub-id-type="pmid">21502576</pub-id></element-citation></ref><ref id="b25-vhrm-8-621"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blonde</surname><given-names>L</given-names></name><name><surname>Klein</surname><given-names>EJ</given-names></name><name><surname>Han</surname><given-names>J</given-names></name><etal/></person-group><article-title>Interim analysis of the effects of exenatide
treatment on A<sub>1c</sub>, weight and cardiovascular risk factors over 82
weeks in 314 overweight patients with type 2
diabetes</article-title><source>Diabetes Obes
Metab</source><year>2006</year><volume>8</volume><issue>4</issue><fpage>436</fpage><lpage>447</lpage><pub-id pub-id-type="pmid">16776751</pub-id></element-citation></ref><ref id="b26-vhrm-8-621"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klonoff</surname><given-names>DC</given-names></name><name><surname>Buse</surname><given-names>JB</given-names></name><name><surname>Nielsen</surname><given-names>LL</given-names></name><etal/></person-group><article-title>Exenatide effects on diabetes, obesity,
cardiovascular risk factors and hepatic biomarkers in patients with type 2
diabetes treated for at least 3 years</article-title><source>Curr Med Res
Opin</source><year>2008</year><volume>24</volume><issue>1</issue><fpage>275</fpage><lpage>286</lpage><pub-id pub-id-type="pmid">18053320</pub-id></element-citation></ref><ref id="b27-vhrm-8-621"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwartz</surname><given-names>EA</given-names></name><name><surname>Koska</surname><given-names>J</given-names></name><name><surname>Mullin</surname><given-names>MP</given-names></name><name><surname>Syoufi</surname><given-names>I</given-names></name><name><surname>Schwenke</surname><given-names>DC</given-names></name><name><surname>Reaven</surname><given-names>PD</given-names></name></person-group><article-title>Exenatide suppresses postprandial elevations in
lipids and lipoproteins in individuals with impaired glucose tolerance and
recent onset type 2 diabetes
mellitus</article-title><source>Atherosclerosis</source><year>2010</year><volume>212</volume><issue>1</issue><fpage>217</fpage><lpage>222</lpage><pub-id pub-id-type="pmid">20557887</pub-id></element-citation></ref><ref id="b28-vhrm-8-621"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bergenstal</surname><given-names>RM</given-names></name><name><surname>Wysham</surname><given-names>C</given-names></name><name><surname>Macconell</surname><given-names>L</given-names></name><etal/></person-group><article-title>Efficacy and safety of exenatide once weekly
versus sitagliptin or pioglitazone as an adjunct to metformin for treatment
of type 2 diabetes (DURATION-2): a randomised
trial</article-title><source>Lancet</source><year>2010</year><volume>376</volume><issue>9739</issue><fpage>431</fpage><lpage>439</lpage><pub-id pub-id-type="pmid">20580422</pub-id></element-citation></ref><ref id="b29-vhrm-8-621"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wysham</surname><given-names>C</given-names></name><name><surname>Bergenstal</surname><given-names>R</given-names></name><name><surname>Malloy</surname><given-names>J</given-names></name><etal/></person-group><article-title>DURATION-2: efficacy and safety of switching from
maximum daily sitagliptin or pioglitazone to once-weekly
exenatide</article-title><source>Diabet
Med</source><year>2011</year><volume>28</volume><issue>6</issue><fpage>705</fpage><lpage>714</lpage><pub-id pub-id-type="pmid">21434995</pub-id></element-citation></ref><ref id="b30-vhrm-8-621"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>C</given-names></name><name><surname>Bandsma</surname><given-names>RH</given-names></name><name><surname>Dash</surname><given-names>S</given-names></name><name><surname>Szeto</surname><given-names>L</given-names></name><name><surname>Lewis</surname><given-names>GF</given-names></name></person-group><article-title>Exenatide, a glucagon- like peptide receptor
agonist, acutely inhibits intestinal lipoprotein production in healthy
humans</article-title><source>Arterioscler Thromb Vasc
Biol</source><year>2012</year><volume>32</volume><issue>6</issue><fpage>1513</fpage><lpage>1519</lpage><pub-id pub-id-type="pmid">22492091</pub-id></element-citation></ref><ref id="b31-vhrm-8-621"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bays</surname><given-names>H</given-names></name><name><surname>Mandarino</surname><given-names>L</given-names></name><name><surname>DeFronzo</surname><given-names>RA</given-names></name></person-group><article-title>Role of the adipocyte, free fatty acids, and
ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal
proliferator-activated receptor agonists provide a rational therapeutic
approach</article-title><source>J Clin Endocrinol
Metab</source><year>2004</year><volume>89</volume><issue>2</issue><fpage>463</fpage><lpage>478</lpage><pub-id pub-id-type="pmid">14764748</pub-id></element-citation></ref><ref id="b32-vhrm-8-621"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soinio</surname><given-names>M</given-names></name><name><surname>Marniemi</surname><given-names>J</given-names></name><name><surname>Laakso</surname><given-names>M</given-names></name><name><surname>Lehto</surname><given-names>S</given-names></name><name><surname>Ronnemaa</surname><given-names>T</given-names></name></person-group><article-title>High-sensitivity C-reactive protein and coronary
heart disease mortality in patients with type 2 diabetes: a 7-year follow-up
study</article-title><source>Diabetes
Care</source><year>2006</year><volume>29</volume><issue>2</issue><fpage>329</fpage><lpage>333</lpage><pub-id pub-id-type="pmid">16443882</pub-id></element-citation></ref><ref id="b33-vhrm-8-621"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>JD</given-names></name><name><surname>Xu</surname><given-names>XH</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Effect of exenatide on inflammatory and oxidative
stress markers in patients with type 2 diabetes
mellitus</article-title><source>Diabetes Technol
Ther</source><year>2011</year><volume>13</volume><issue>2</issue><fpage>143</fpage><lpage>148</lpage><pub-id pub-id-type="pmid">21284481</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f1-vhrm-8-621" position="float"><label>Figure 1</label><caption><p>Effects of exenatide on glycosylated hemoglobin, body weight,
apolipoproteins, and lipoproteins in the total analysis cohort with an
overall normal lipid profile at baseline. Week 30 change data are
independent of glycemic improvement and weight loss. (<bold>A</bold>)
Glycosylated hemoglobin. (<bold>B</bold>) Body weight. (<bold>C</bold>)
Apolipoprotein B. (<bold>D</bold>) Percentage of apolipoprotein
B/apolipoprotein A1. (<bold>E</bold>) Low-density lipoprotein cholesterol
and its subclasses. (<bold>F</bold>) Triglycerides, very low-density
lipoprotein cholesterol, and non-high-density lipoprotein cholesterol.
(<bold>G</bold>) High-density lipoprotein cholesterol and its
subclasses. (<bold>H</bold>) Percentage changes in high-density lipoprotein
cholesterol and its subclasses. (Panels <bold>A</bold> and <bold>B</bold>)
Least squares mean + 95% confidence intervals.
*Change from baseline <italic>P</italic> &#x0003c; 0.0001. (Panels
<bold>C</bold>&#x02013;<bold>G</bold>) Adjusted mean + standard
error of the mean.</p><p><bold>Notes:</bold> *Week 30 change from baseline <italic>P</italic>
&#x0003c; 0.05. Once weekly, n = 106, twice daily, n = 105.</p><p><bold>Abbreviations:</bold> A<sub>1c</sub>, glycosylated hemoglobin; ApoB,
apolipoprotein B; ApoA1, apolipoprotein A1; BID, twice daily; LDL-C,
low-density lipoprotein cholesterol; VLDL-C, very low-density lipoprotein
cholesterol; HDL-C, high-density lipoprotein cholesterol; QW, once
weekly.</p></caption><graphic xlink:href="vhrm-8-621f1"/></fig><fig id="f2-vhrm-8-621" position="float"><label>Figure 2</label><caption><p>Effects of exenatide on apolipoproteins, lipoproteins, and high sensitivity
C-reactive protein in the subgroup of patients with abnormal lipid
values<xref ref-type="bibr" rid="b1-vhrm-8-621">1</xref>&#x02013;<xref ref-type="bibr" rid="b3-vhrm-8-621">3</xref> at baseline.
(<bold>A</bold>) Apolipoprotein A1, apolipoprotein B, and the ratio of
these apolipoproteins; once weekly, n = 85, n = 9, and n
= 22, respectively; twice daily, n = 78, 18, and 29,
respectively. (<bold>B</bold>) Low-density lipoprotein cholesterol and
subclass ratios; once weekly, n = 28, 28, and 28, respectively;
twice daily, n = 36, 36, and 36, respectively. (<bold>C</bold>)
Triglycerides, very low-density lipoprotein (VLDL) cholesterol, VLDL3
cholesterol, ratio of VLDL cholesterol/VLDL3 cholesterol, and
intermediate-density lipoprotein cholesterol; once weekly, n = 55,
18, 77, 106, and 7, respectively; twice daily, n = 52, 20, 75, 104,
and 6, respectively. (<bold>D</bold>) Non-high-density lipoprotein
cholesterol and remnant lipoproteins; once weekly, n = 26 and n
= 13, respectively; and twice daily, n = 34 and n =
21, respectively. (<bold>E</bold>) Total high-density lipoprotein
cholesterol and its subclasses stratified by gender and overall subclass
ratio; once weekly, n = 51, 39, 57, 22, 47, and 95, respectively;
twice daily, n = 46, 39, 55, 17, 44, and 96, respectively.
(<bold>F</bold>) High sensitivity C-reactive protein in the total
cohort; once weekly, n = 104; twice daily, n = 103.</p><p><bold>Notes:</bold> High sensitivity C-reactive protein in the subgroup with
baseline &#x0003e; 3 mg/L and &#x0003c;10 mg/L; once weekly, n = 41; twice
daily, n = 32. Adjusted mean + standard error of the mean.
*Week 30 change from baseline <italic>P</italic> &#x0003c; 0.05.</p><p><bold>Abbreviations:</bold> BL, baseline; ApoB, apolipoprotein B; ApoA1,
apolipoprotein A1; LDL-C, low-density lipoprotein cholesterol; BID, twice
daily; HDL-C, high-density lipoprotein cholesterol; VLDL-C, very low-density
lipoprotein cholesterol; IDL-C, intermediate-density lipoprotein
cholesterol; RLPs, remnant lipoproteins; hsCRP, high sensitivity C-reactive
protein; QW, once weekly.</p></caption><graphic xlink:href="vhrm-8-621f2"/></fig><table-wrap id="t1-vhrm-8-621" position="float"><label>Table 1</label><caption><p>Demographics and baseline characteristics for the lipoprotein subclass
analysis cohort</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1"/><th colspan="2" align="left" valign="top" rowspan="1">Total cohort</th></tr><tr><th align="left" valign="top" rowspan="1" colspan="1"/><th colspan="2" align="left" valign="top" rowspan="1">
<hr/></th></tr><tr><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">ExQW<break/>n = 106</th><th align="left" valign="top" rowspan="1" colspan="1">ExBID<break/>n = 105</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Age (years)</td><td align="left" valign="top" rowspan="1" colspan="1">56 &#x000b1; 9</td><td align="left" valign="top" rowspan="1" colspan="1">55 &#x000b1; 10</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Female (%)</td><td align="left" valign="top" rowspan="1" colspan="1">36.8</td><td align="left" valign="top" rowspan="1" colspan="1">47.6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Caucasian (%)</td><td align="left" valign="top" rowspan="1" colspan="1">84.9</td><td align="left" valign="top" rowspan="1" colspan="1">73.3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Black/African American (%)</td><td align="left" valign="top" rowspan="1" colspan="1">4.7</td><td align="left" valign="top" rowspan="1" colspan="1">11.4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hispanic (%)</td><td align="left" valign="top" rowspan="1" colspan="1">10.4</td><td align="left" valign="top" rowspan="1" colspan="1">14.3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Asian (%)</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">1.0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">A<sub>1c</sub> (%)</td><td align="left" valign="top" rowspan="1" colspan="1">8.2 &#x000b1; 0.9</td><td align="left" valign="top" rowspan="1" colspan="1">8.2 &#x000b1; 0.9</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Body weight (kg)</td><td align="left" valign="top" rowspan="1" colspan="1">101 &#x000b1; 18</td><td align="left" valign="top" rowspan="1" colspan="1">104 &#x000b1; 22</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="left" valign="top" rowspan="1" colspan="1">34.8 &#x000b1; 5.0</td><td align="left" valign="top" rowspan="1" colspan="1">34.9 &#x000b1; 5.3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Apolipoprotein A (g/L)</td><td align="left" valign="top" rowspan="1" colspan="1">1.3 &#x000b1; 0.2</td><td align="left" valign="top" rowspan="1" colspan="1">1.3 &#x000b1; 0.2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Apolipoprotein B (g/L)</td><td align="left" valign="top" rowspan="1" colspan="1">0.81 &#x000b1; 0.21</td><td align="left" valign="top" rowspan="1" colspan="1">0.86 &#x000b1; 0.23</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Apolipoprotein B/A1 (%)</td><td align="left" valign="top" rowspan="1" colspan="1">61 &#x000b1; 15</td><td align="left" valign="top" rowspan="1" colspan="1">65 &#x000b1; 17</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Triglycerides (mmol/L)</td><td align="left" valign="top" rowspan="1" colspan="1">2.14 &#x000b1; 1.40</td><td align="left" valign="top" rowspan="1" colspan="1">2.11 &#x000b1; 1.44</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LDL-C (mmol/L)</td><td align="left" valign="top" rowspan="1" colspan="1">2.16 &#x000b1; 0.80</td><td align="left" valign="top" rowspan="1" colspan="1">2.42 &#x000b1; 0.94</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;LDL1-C (mmol/L)</td><td align="left" valign="top" rowspan="1" colspan="1">0.22 &#x000b1; 0.17</td><td align="left" valign="top" rowspan="1" colspan="1">0.27 &#x000b1; 0.19</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;LDL2-C (mmol/L)</td><td align="left" valign="top" rowspan="1" colspan="1">0.17 &#x000b1; 0.19</td><td align="left" valign="top" rowspan="1" colspan="1">0.23 &#x000b1; 0.28</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;LDL3-C (mmol/L)</td><td align="left" valign="top" rowspan="1" colspan="1">0.75 &#x000b1; 0.36</td><td align="left" valign="top" rowspan="1" colspan="1">0.82 &#x000b1; 0.43</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;LDL4-C (mmol/L)</td><td align="left" valign="top" rowspan="1" colspan="1">0.54 &#x000b1; 0.29</td><td align="left" valign="top" rowspan="1" colspan="1">0.56 &#x000b1; 0.29</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">VLDL-C (mmol/L)</td><td align="left" valign="top" rowspan="1" colspan="1">0.59 &#x000b1; 0.20</td><td align="left" valign="top" rowspan="1" colspan="1">0.60 &#x000b1; 0.21</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HDL-C (mmol/L)</td><td align="left" valign="top" rowspan="1" colspan="1">1.04 &#x000b1; 0.24</td><td align="left" valign="top" rowspan="1" colspan="1">1.06 &#x000b1; 0.27</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;HDL-2 (mmol/L)</td><td align="left" valign="top" rowspan="1" colspan="1">0.20 &#x000b1; 0.09</td><td align="left" valign="top" rowspan="1" colspan="1">0.20 &#x000b1; 0.09</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;HDL-3 (mmol/L)</td><td align="left" valign="top" rowspan="1" colspan="1">0.84 &#x000b1; 0.16</td><td align="left" valign="top" rowspan="1" colspan="1">0.86 &#x000b1; 0.20</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1">Diabetes medications
(%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;None</td><td align="left" valign="top" rowspan="1" colspan="1">15.2</td><td align="left" valign="top" rowspan="1" colspan="1">10.4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;MET alone</td><td align="left" valign="top" rowspan="1" colspan="1">34.9</td><td align="left" valign="top" rowspan="1" colspan="1">33.3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;SFU alone</td><td align="left" valign="top" rowspan="1" colspan="1">2.8</td><td align="left" valign="top" rowspan="1" colspan="1">6.7</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;TZD alone</td><td align="left" valign="top" rowspan="1" colspan="1">1.9</td><td align="left" valign="top" rowspan="1" colspan="1">14.3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;MET + TZD</td><td align="left" valign="top" rowspan="1" colspan="1">11.3</td><td align="left" valign="top" rowspan="1" colspan="1">3.8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;MET + SFU</td><td align="left" valign="top" rowspan="1" colspan="1">29.2</td><td align="left" valign="top" rowspan="1" colspan="1">26.7</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;TZD + SFU</td><td align="left" valign="top" rowspan="1" colspan="1">3.8</td><td align="left" valign="top" rowspan="1" colspan="1">2.9</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;MET + TZD +
SFU</td><td align="left" valign="top" rowspan="1" colspan="1">0.9</td><td align="left" valign="top" rowspan="1" colspan="1">1.9</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1">Dyslipidemia medications
(%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Statin</td><td align="left" valign="top" rowspan="1" colspan="1">61.3</td><td align="left" valign="top" rowspan="1" colspan="1">44.8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Statin + CAI</td><td align="left" valign="top" rowspan="1" colspan="1">7.5</td><td align="left" valign="top" rowspan="1" colspan="1">5.7</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Niacin</td><td align="left" valign="top" rowspan="1" colspan="1">2.8</td><td align="left" valign="top" rowspan="1" colspan="1">4.8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Fibrate</td><td align="left" valign="top" rowspan="1" colspan="1">7.5</td><td align="left" valign="top" rowspan="1" colspan="1">9.5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;CAI</td><td align="left" valign="top" rowspan="1" colspan="1">8.5</td><td align="left" valign="top" rowspan="1" colspan="1">4.8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Fish oil</td><td align="left" valign="top" rowspan="1" colspan="1">7.5</td><td align="left" valign="top" rowspan="1" colspan="1">5.7</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-vhrm-8-621"><p><bold>Note:</bold> Values are mean &#x000b1; SD.</p></fn><fn id="tfn2-vhrm-8-621"><p><bold>Abbreviations:</bold> ApoB, apolipoprotein B; ApoA1, apolipoprotein
A1; BMI, body mass index; LDL-C, low-density lipoprotein cholesterol;
HDL-C, high-density lipoprotein cholesterol; VLDL-C, very low-density
lipoprotein cholesterol; CAI, cholesterol absorption inhibitor; MET,
metformin; SD, standard deviation; SFU, sulfonylurea; TZD,
thiazolidinedione; A<sub>1c</sub>, glycosylated hemoglobin; ExQW,
exenatide once weekly; ExBID, exenatide twice daily.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-vhrm-8-621" position="float"><label>Table 2</label><caption><p>Apolipoprotein and lipoprotein change from baseline in patients with type
treated with exenatide for 30 weeks for the lipoprotein subclass analysis
cohort</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1"/><th align="left" valign="top" rowspan="1" colspan="1">ExQW<break/>(n = 106)</th><th align="left" valign="top" rowspan="1" colspan="1">ExBID<break/>(n = 105)</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">ApoA1 (g/L)</td><td align="left" valign="top" rowspan="1" colspan="1">0.016 (&#x02212;0.011, 0.042)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.001 (&#x02212;0.028,
0.025)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ApoB (g/L)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.036<xref ref-type="table-fn" rid="tfn4-vhrm-8-621">*</xref> (&#x02212;0.065,
&#x02212;0.008)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.013 (&#x02212;0.041,
0.015)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ApoB/ApoA1 (%)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;3.1 (&#x02212;5.0,
&#x02212;1.3)<xref ref-type="table-fn" rid="tfn4-vhrm-8-621">*</xref></td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;1.0 (&#x02212;2.8, 0.9)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Triglycerides (mmol/L)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.361 (&#x02212;0.566,
&#x02212;0.155)<xref ref-type="table-fn" rid="tfn4-vhrm-8-621">*</xref></td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.339 (&#x02212;0.546,
&#x02212;0.132)<xref ref-type="table-fn" rid="tfn4-vhrm-8-621">*</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LDL-C (mmol/L)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.073 (&#x02212;0.192,
0.028)</td><td align="left" valign="top" rowspan="1" colspan="1">0.009 (&#x02212;0.111, 0.129)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LDL1-C (mmol/L)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.008 (&#x02212;0.035,
0.019)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.006 (&#x02212;0.034,
0.021)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LDL2-C (mmol/L)</td><td align="left" valign="top" rowspan="1" colspan="1">0.024 (&#x02212;0.008, 0.055)</td><td align="left" valign="top" rowspan="1" colspan="1">0.012 (&#x02212;0.019, 0.044)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LDL3-C (mmol/L)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.020 (&#x02212;0.080,
0.040)</td><td align="left" valign="top" rowspan="1" colspan="1">0.050 (&#x02212;0.011, 0.110)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LDL4-C (mmol/L)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.052 (&#x02212;0.098,
&#x02212;0.006)<xref ref-type="table-fn" rid="tfn4-vhrm-8-621">*</xref></td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.015 (&#x02212;0.061,
0.031)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IDL-C (mmol/L)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.005 (&#x02212;0.025,
0.015)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.005 (&#x02212;0.025,
0.015)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">VLDL-C (mmol/L)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.327 (&#x02212;0.360,
&#x02212;0.295)<xref ref-type="table-fn" rid="tfn4-vhrm-8-621">*</xref></td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.343 (&#x02212;0.375,
&#x02212;0.310)<xref ref-type="table-fn" rid="tfn4-vhrm-8-621">*</xref></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">VLDL3-C (mmol/L)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.007 (&#x02212;0.022,
0.008)</td><td align="left" valign="top" rowspan="1" colspan="1">0.004 (&#x02212;0.011, 0.019)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">VLDL12-C (mmol/L)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.004 (&#x02212;0.026,
0.018)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.007 (&#x02212;0.029,
0.015)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">nonHDL-C (mmol/L)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.086 (&#x02212;0.220,
0.049)</td><td align="left" valign="top" rowspan="1" colspan="1">0.015 (&#x02212;0.120, 0.151)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">RLPs (mmol/L)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.012 (&#x02212;0.044 0.020)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.001 (&#x02212;0.034,
0.031)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Lp(a) (mmol/L)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.012 (&#x02212;0.040,
0.016)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.023 (&#x02212;0.051,
0.005)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HDL-C (mmol/L)</td><td align="left" valign="top" rowspan="1" colspan="1">0.032 (&#x02212;0.000, 0.065)</td><td align="left" valign="top" rowspan="1" colspan="1">0.005 (&#x02212;0.027, 0.038)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HDL2-C (mmol/L)</td><td align="left" valign="top" rowspan="1" colspan="1">0.013 (0.002, 0.025)<xref ref-type="table-fn" rid="tfn4-vhrm-8-621">*</xref></td><td align="left" valign="top" rowspan="1" colspan="1">0.005 (&#x02212;0.007, 0.017)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HDL3-C (mmol/L)</td><td align="left" valign="top" rowspan="1" colspan="1">0.018 (&#x02212;0.007, 0.043)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x02212;0.002 (&#x02212;0.027,
0.023)</td></tr></tbody></table><table-wrap-foot><fn id="tfn3-vhrm-8-621"><p><bold>Notes:</bold> Values are adjusted mean (95% CI).</p></fn><fn id="tfn4-vhrm-8-621"><label>*</label><p><italic>P</italic> &#x0003c; 0.05 versus baseline. Adjusted model included
changes from baseline in A<sub>1c</sub> and weight as covariates.</p></fn><fn id="tfn5-vhrm-8-621"><p><bold>Abbreviations:</bold> ApoB, apolipoprotein B; ApoA1, apolipoprotein
A1; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density
lipoprotein cholesterol; VLDL-C, very low-density lipoprotein
cholesterol; A<sub>1c</sub>, glycosylated hemoglobin; Lp(a),
lipoprotein(a); RLPs, remnant lipoproteins; ExQW, exenatide once weekly;
ExBID, exenatide twice daily.</p></fn></table-wrap-foot></table-wrap></floats-group></article>